Aptevo Therapeutics Expands Bispecific Antibody Portfolio

20:00 EDT 13 Mar 2017 | Globe Newswire

SEATTLE, March 14, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that preclinical data for new bispecific antibody candidates targeting CD123 and CD3 will be presented in a poster session at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Washington D.C., April 1-5, 2017.

Based on Aptevo’s proprietary ADAPTIR™ protein therapeutic platform, the Company’s latest bispecific candidates targeting CD123 were designed to redirect T-cell cytotoxicity to CD123-expressing tumors cells, a cell surface receptor highly expressed in several hematological malignancies.  Results being presented at AACR will examine the in vitro and in vivo activity of optimized lead candidates, APVO436 and APVO437, in preclinical models of acute myeloid leukemia (AML).

Title: Bispecific anti-CD123 x anti-CD3 ADAPTIR Molecules for Redirected T-cell Cytotoxicity  in Hematological Malignancies   
Date/Time: April 2, 2017 – 1:00 – 5:00 pm ET
Session Title: T-Cell Immunity to Cancer – New Progress (Immunology)
Abstract ID: 597/1

Abstracts for the AACR annual meeting are available and can be viewed online at  Aptevo’s poster presentation will be available on the Investor Relations section of the Company’s website at following the poster session.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.

Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications


More From BioPortfolio on "Aptevo Therapeutics Expands Bispecific Antibody Portfolio"

Quick Search


Relevant Topics

Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...